PriceTargets.com logo

Avalo Therapeutics - AVTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $40.00
  • Forecasted Upside: 348.93%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.91 As of 12/20/2024 06:31 PM ET
▼ -0.17 (-1.87%)

This chart shows the closing price for AVTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Avalo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVTX

Analyst Price Target is $40.00
▲ +348.93% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Avalo Therapeutics in the last 3 months. The average price target is $40.00, with a high forecast of $40.00 and a low forecast of $40.00. The average price target represents a 348.93% upside from the last price of $8.91.

This chart shows the closing price for AVTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 polled investment analysts is to moderate buy stock in Avalo Therapeutics. This rating has held steady since October 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/19/2024BTIG ResearchInitiated CoverageBuy$40.00
10/24/2024HC WainwrightInitiated CoverageNeutral
4/16/2024OppenheimerUpgradeMarket Perform ➝ Outperform
6/27/2023OppenheimerDowngradeOutperform ➝ Market Perform
6/27/2023Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
2/8/2023Jefferies Financial GroupDowngradeHold ➝ Underperform
11/15/2022OppenheimerLower Target$2,400.00
11/9/2022OppenheimerLower Target$4,080.00 ➝ $2,400.00
7/11/2022Royal Bank of CanadaLower Target$5,760.00 ➝ $5,040.00
3/3/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$14,400.00 ➝ $2,160.00
3/3/2022Royal Bank of CanadaLower TargetOutperform$14,400.00 ➝ $11,520.00
1/7/2022OppenheimerReiterated RatingBuy$14,400.00
9/24/2021Royal Bank of CanadaInitiated CoverageOutperform$17,280.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Avalo Therapeutics logo
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $8.91
Low: $8.67
High: $9.81

50 Day Range

MA: $11.13
Low: $8.91
High: $14.44

52 Week Range

Now: $8.91
Low: $3.95
High: $34.46

Volume

949,861 shs

Average Volume

205,439 shs

Market Capitalization

$92.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Avalo Therapeutics?

The following sell-side analysts have issued reports on Avalo Therapeutics in the last twelve months: BTIG Research, HC Wainwright, and Oppenheimer Holdings Inc..
View the latest analyst ratings for AVTX.

What is the current price target for Avalo Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Avalo Therapeutics in the last year. Their average twelve-month price target is $40.00, suggesting a possible upside of 348.9%. BTIG Research has the highest price target set, predicting AVTX will reach $40.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $40.00 for Avalo Therapeutics in the next year.
View the latest price targets for AVTX.

What is the current consensus analyst rating for Avalo Therapeutics?

Avalo Therapeutics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AVTX.

What other companies compete with Avalo Therapeutics?

Other companies that are similar to Avalo Therapeutics include Cryoport, Neurogene, Procaps Group, biote and Design Therapeutics. Learn More about companies similar to Avalo Therapeutics.

How do I contact Avalo Therapeutics' investor relations team?

Avalo Therapeutics' physical mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The company's listed phone number is (410) 522-8707 and its investor relations email address is [email protected]. The official website for Avalo Therapeutics is www.avalotx.com. Learn More about contacing Avalo Therapeutics investor relations.